Outcome of allogeneic bone marrow transplantation with lymphocyte-depleted marrow grafts in adult patients with myelodysplastic syndromes

Bone Marrow Transplantation

Volumn 19, Issue 8, 1997, Pages 791-794

  Mattijssen, V ^a   Schattenberg, A ^a   Schaap, N ^a   Preijers, F ^a   De Witte, T ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bone marrow transplantation; Myelodysplastic syndromes

Indexed keywords

CYCLOPHOSPHAMIDE; IDARUBICIN;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CENTRIFUGATION; CLINICAL ARTICLE; DONOR; FEMALE; GENOTYPE; HLA TYPING; HUMAN; LYMPHOCYTE; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REFRACTORY ANEMIA; REMISSION; T LYMPHOCYTE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 0030988212     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700739     Document Type: Article

References (19)

1. Aul C, Gattermann N, Schneider W. Epidemiological and etiological aspects of myelodysplastic syndromes. Lenk Lymphoma 1995; 16: 247-262.
2. De Witte T. New treatment approaches for myelodysplastic syndrome and secondary leukaemias. Ann Oncol 1994; 5: 401-408.
3. De Witte T, Muus P, De Pauw B, Haanen C, Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer 1990; 66: 831-837.
4. De Witte T, Suciu S, Peetermans M et al. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia 1995; 9: 1805-1811.
5. Kantarjian HM, Keating MJ, Walters RS et al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol 1986; 4: 1748-1757.
6. Anderson JE, Appelbaum FR, Storb R. An update on allogeneic marrow transplantation for myelodysplastic syndrome. Leuk Lymphoma 1995; 17: 95-99.
7. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
8. De Witte T, Raymakers R, Plas A et al. Bone marrow repopulation capacity after transplantation of lymphocyte depleted allogeneic bone marrow using counterflow centrifugation. Transplantation 1984; 37: 151-155.
9. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
10. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graftversus-host syndrome in man. Am J Med 1980; 69: 204-217.
11. O'Donnell MR, Nademanee AP, Snyder DS et al. Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J Clin Oncol 1987; 5: 1822-1826.
12. De Witte T, Zwaan F, Hermans J et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 1990; 74: 151-155.
13. Longmore G, Guinan EC, Weinstein HJ et al. Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia. J Clin Oncol 1990; 8: 1707-1714.
14. Sutton L, Leblond V, Le Maignan C et al. Bone marrow transplantation for myelodysplastic syndrome and secondary leukemia: outcome of 86 patients. Bone Marrow Transplant 1991; 7 (Suppl): 39.
15. Nevill TJ, Shepherd JD, Reece DE et al. Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant 1992; 10: 445-450.
16. Ratanatharathorn V, Karanes C, Uberti J et al. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood 1993; 81: 2194-2199.
17. O'Donnell MR, Long GD, Parker PM et al. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol 1995; 13: 2973-2979.
18. Anderson JE, Appelbaum FR, Schoch G et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 1996; 14: 220-226.
19. Anderson JE, Appelbaum FR, Schoch G et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood 1996; 87: 51-58.